Abstract
Male-specific late effects after hematopoietic cell transplantation (HCT) include genital chronic graft-versus-host disease (GvHD), hypogonadism, sexual dysfunction, infertility, and subsequent malignancies. They may be closely intertwined and cause prolonged morbidity and decreased quality of life after HCT. We provide a systematic review of male-specific late effects in a collaboration between transplant physicians, endocrinologists, urologists, dermatologists, and sexual health professionals through the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research, and the Transplant Complications Working Party of the European Society of Blood and Marrow Transplantation. The systematic review summarizes incidence, risk factors, screening, prevention and treatment of these complications and provides consensus evidence-based recommendations for clinical practice and future research.
Original language | English (US) |
---|---|
Pages (from-to) | 1150-1163 |
Number of pages | 14 |
Journal | Bone Marrow Transplantation |
Volume | 57 |
Issue number | 7 |
DOIs | |
State | Published - Jul 2022 |
Funding
HE reports grants and other from BMS/Celgene, grants and other from Janssen, grants and other from Amgen, other from Takeda, grants and other from Sanofi, grants and other from GSK, during the conduct of the study. SH reports other from Pfizer, other from Novartis, other from Therakos, other from Janssen, other from MSD, outside the submitted work. YI reports personal fees from Novartis, personal fees from Janssen, personal fees from Meiji Seika Pharma, outside the submitted work. RP reports research funding from Amgen. RR reports other from Diurnal Plc, during the conduct of the study. HS reports participation in advisory boards for Janssen & Novartis; speaker\u2019s fees from Incyte, Jazz Pharmaceuticals, Takeda, Novartis and the BHS (Belgian Hematological Society); travel grants from EBMT, CIBMTR, Incyte & Gilead and research funding from Novartis & the BHS, outside of the submitted work. AR reports grants from Novartis, grants from CSL Behring, grants from Alexion, personal fees from Novartis, personal fees from BMS, personal fees from OrPha Swiss GmbH, other from Amgen, other from AstraZeneca, other from Sanofi, other from Celgene, outside the submitted work. ASharma reports clinical trial salary support from Vertex Pharmaceuticals, CRISPR Therapeutics, Novartis paid to his institution, and personal consultancy fees from Spotlight Therapeutics, outside the submitted work. JAS reports personal fees from MEDAC, personal fees from KIADIS, personal fees from GILEAD, personal fees from JANSSEN, personal fees from MALLINCKRODT, personal fees from JAZZ, personal fees from ACTELION, outside the submitted work. DW reports grants and personal fees from Novartis, personal fees from Mallinckrodt, personal fees from Behring, outside the submitted work. PG is a consultant to Ascenage Pharma, BeiGene Ltd, Kite Pharma Inc., Fusion Pharma LLC, LaJolla NanoMedical Inc., Mingsight Parmaceuticals Inc. and CStone Pharmaceuticals; Medical Director, FFF Enterprises Inc.; Partner, AZCA Inc.; Board of Directors, RakFond Foundation for Cancer Research Support; Scientific Advisory Board, Antegene Biotech LLC and StemRad Ltd. The CIBMTR is supported primarily by Public Health Service U24CA076518 from the National Cancer Institute (NCI), the National Heart, Lung and Blood Institute (NHLBI) and the National Institute of Allergy and Infectious Diseases (NIAID); HHSH250201700006C from the Health Resources and Services Administration (HRSA); and N00014-20-1-2705 and N00014-20-1-2832 from the Office of Naval Research; Support is also provided by Be the Match Foundation, the Medical College of Wisconsin, the National Marrow Donor Program, and from the following commercial entities: AbbVie; Accenture; Actinium Pharmaceuticals, Inc.; Adaptive Biotechnologies Corporation; Adienne SA; Allovir, Inc.; Amgen, Inc.; Astellas Pharma US; bluebird bio, inc.; Bristol Myers Squibb Co.; CareDx; CSL Behring; CytoSen Therapeutics, Inc.; Daiichi SankyoCo., Ltd; Eurofins Viracor; ExcellThera; Fate Therapeutics; Gamida-Cell, Ltd; Genentech Inc; Gilead; GlaxoSmithKline; Incyte Corporation; Janssen/Johnson & Johnson; Jasper Therapeutics; Jazz Pharmaceuticals, Inc.; Karyopharm Therapeutics; Kiadis Pharma; Kite, a Gilead Company; Kyowa Kirin; Magenta Therapeutics; Medac GmbH; Merck & Co.; Millennium, the Takeda Oncology Co.; Miltenyi Biotec, Inc.; MorphoSys; Novartis Pharmaceuticals Corporation; Omeros Corporation; Oncopeptides, Inc.; Orca Biosystems, Inc.; Pfizer, Inc.; Pharmacyclics, LLC; Sanofi Genzyme; Seagen, Inc.; Stemcyte; Takeda Pharmaceuticals; Tscan; Vertex; Vor Biopharma; Xenikos BV.
ASJC Scopus subject areas
- Hematology
- Transplantation